EFEMP1

Chr 2ARAD

EGF-like fibulin extracellular matrix protein 1

Also known as: ARCL1D, DHRD, DRAD, FBLN3, FBNL, FIBL-3, GLC1H, MLVT

This gene encodes a member of the fibulin family of extracellular matrix glycoproteins. Like all members of this family, the encoded protein contains tandemly repeated epidermal growth factor-like repeats followed by a C-terminus fibulin-type domain. This gene is upregulated in malignant gliomas and may play a role in the aggressive nature of these tumors. Mutations in this gene are associated with Doyne honeycomb retinal dystrophy. Alternatively spliced transcript variants that encode the same protein have been described.[provided by RefSeq, Nov 2009]

OMIMResearchGenerating clinical summary…
MultiplemechanismAR/ADLOEUF 0.153 OMIM phenotypes
Clinical SummaryEFEMP1
🧬
Gene-Disease Validity (ClinGen)
Doyne honeycomb retinal dystrophy · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

2 total gene-disease associations curated

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
1 unique Pathogenic / Likely Pathogenic· 8 VUS of 36 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?
0.15LOEUF
pLI 1.000
Z-score 4.99
OE 0.03 (0.010.15)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?
1.82Z-score
OE missense 0.69 (0.610.78)
192 obs / 277.5 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.03 (0.010.15)
00.351.4
Missense OE?0.69 (0.610.78)
00.61.4
Synonymous OE?1.10
01.21.6
LoF obs/exp: 1 / 31.0Missense obs/exp: 192 / 277.5Syn Z: -0.83
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveEFEMP1-related Doyne honeycomb degeneration of retinaOTHERAD

This gene — mechanism propensity

DN
0.4983th %ile
GOF
0.4776th %ile
LOF
0.59top 25%

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to loss-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFLOEUF 0.15
GOF1 literature citation

Literature Evidence

GOFA recurrent gain-of-function variant (p.(Arg345Trp)) in EFEMP1 has previously been associated with Doyne honeycomb retinal dystrophy.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 33807164

ClinVar Variant Classifications

36 submitted variants in ClinVar

Classification Summary

Likely Pathogenic1
VUS8
Likely Benign4
Benign20
Conflicting3
1
Likely Pathogenic
8
VUS
4
Likely Benign
20
Benign
3
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
0
0
0
Likely Pathogenic
0
1
0
0
1
VUS
0
2
5
1
8
Likely Benign
0
0
2
2
4
Benign
0
1
16
3
20
Conflicting
3
Total0423636

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

2 pathogenic / likely-pathogenic (of 4) ClinVar copy-number / structural variants overlap EFEMP1 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

EFEMP1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →